Liquidia (NASDAQ:LQDA) Insider Jason Adair Sells 35,656 Shares

Liquidia Corporation (NASDAQ:LQDA) insider Jason Adair sold 35,656 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $30.03, for a total value of $1,070,749.68. Following the completion of the transaction, the insider directly owned 174,998 shares of the company’s stock, valued at $5,255,189.94. The trade was a 16.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Jason Adair also recently made the following trade(s):

• On Monday, October 27th, Jason Adair sold 692 shares of Liquidia stock. The shares were sold at an average price of $22.93, for a total transaction of $15,867.56.
• On Monday, October 13th, Jason Adair sold 3,670 shares of Liquidia stock. The shares were sold at an average price of $23.41, for a total transaction of $85,914.70.
• On Tuesday, September 2nd, Jason Adair sold 451 shares of Liquidia stock. The stock was sold at an average price of $29.05, for a total transaction of $13,101.55.
• On Tuesday, September 2nd, Jason Adair sold 451 shares of Liquidia stock. The stock was sold at an average price of $29.05, for a total value of $13,101.55.
• On Thursday, August 28th, Jason Adair sold 26,057 shares of Liquidia stock. The stock was sold at an average price of $27.86, for a total transaction of $725,948.02.

Liquidia Price Performance

LQDA traded down $1.08 during midday trading on Thursday, hitting $28.56. 2,416,059 shares of the company traded hands, compared to its average volume of 2,018,155. The company has a market capitalization of $2.48 billion, a price-to-earnings ratio of -19.83 and a beta of 0.12. Liquidia Corporation has a 52-week low of $9.93 and a 52-week high of $30.88. The business has a 50 day simple moving average of $24.50 and a two-hundred day simple moving average of $20.63. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.41. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The company had revenue of $54.34 million during the quarter, compared to analyst estimates of $18.86 million. Liquidia’s revenue for the quarter was up 1106.7% on a year-over-year basis. On average, equities analysts forecast that Liquidia Corporation will post -1.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its holdings in shares of Liquidia by 2.9% in the first quarter. Bank of New York Mellon Corp now owns 194,131 shares of the company’s stock valued at $2,863,000 after purchasing an additional 5,547 shares in the last quarter. Cetera Investment Advisers raised its position in Liquidia by 34.4% in the 1st quarter. Cetera Investment Advisers now owns 41,999 shares of the company’s stock valued at $619,000 after purchasing an additional 10,756 shares in the last quarter. Hurley Capital LLC purchased a new position in shares of Liquidia in the 1st quarter valued at about $32,000. CenterBook Partners LP acquired a new stake in Liquidia in the first quarter valued at approximately $1,786,000. Finally, Aigen Investment Management LP acquired a new position in Liquidia during the 1st quarter worth approximately $151,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on LQDA shares. Wall Street Zen raised shares of Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Jefferies Financial Group restated a “buy” rating and issued a $45.00 price target on shares of Liquidia in a research report on Monday, November 3rd. Needham & Company LLC boosted their price objective on Liquidia from $36.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $47.00 target price on shares of Liquidia in a research note on Tuesday, November 4th. Finally, BTIG Research reiterated a “buy” rating and set a $49.00 price target on shares of Liquidia in a report on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, Liquidia currently has an average rating of “Moderate Buy” and a consensus target price of $38.56.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).